[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"carcinoma-small-cell-lung\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:carcinoma-small-cell-lung":132},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,70,102],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100643392",false,"NCT07640932","Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer","Lurbinectedin in Combination With Paclitaxel Versus Paclitaxel for Patients With Previously Treated Small Cell Lung Cancer: Randomized, Phase II, Open-label, Multi-center, Prospective Trial(LUPINE)","LUPINE","Inclusion Criteria:\n\n1. Age ≥ 19 years.\n2. Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).\n3. Patients who have experienced disease progression following at least one prior platinum-based systemic therapy for extensive-stage small cell lung cancer, including all of the following conditions:\n\n   * Patients who failed treatment within 6 months after curative-intent chemotherapy are considered as having failed first-line therapy.\n   * For platinum-sensitive patients, participation in the third-line cohort is allowed after re-treatment with a platinum-based regimen as second-line therapy (limited-stage).\n   * For platinum-resistant patients, participation in the second-line cohort is allowed (limited-stage).\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n5. At least one measurable target lesion according to RECIST v1.1 criteria.\n6. Predicted life expectancy of at least 12 weeks (3 months).\n7. Adequate hematologic, renal, metabolic, and hepatic function within 14 days prior to enrollment, defined as:\n\n   Absolute neutrophil count (ANC) ≥ 1,500\u002FμL Platelet count ≥ 100,000\u002FμL Hemoglobin (Hb) ≥ 9.0 g\u002FdL Serum creatinine ≤ 1.5 × upper limit of normal (ULN) or calculated creatinine clearance (cCr) ≥ 60 mL\u002Fmin Total bilirubin ≤ 1.0 × ULN AST and ALT ≤ 3.0 × ULN (regardless of liver metastasis) PT and aPTT ≤ 1.5 × ULN\n8. Willingness to provide unstained slides (minimum 5, ideally 15) from archived or freshly biopsied tissue for exploratory analyses.\n9. Female participants of childbearing potential must have a negative pregnancy test (urine) at screening. If the urine test is positive or inconclusive, a negative serum pregnancy test is required.\n\n   Female participants of childbearing potential must agree to use effective contraception during the study.\n10. Male participants of reproductive potential must agree to use effective contraception during the study (see appendix for acceptable methods).\n11. Voluntary written informed consent to participate in this clinical trial.\n\nExclusion Criteria:\n\n1. Patients who have not received prior systemic therapy for small cell lung cancer (SCLC).\n2. Patients previously treated with Lurbinectedin or Paclitaxel.\n3. Patients with limited-stage small cell lung cancer (LS-SCLC).\n4. Patients with symptomatic or clinically significant brain metastases (patients with asymptomatic or stable brain metastases may be eligible; any treatment for brain metastases must have been completed at least 1 week prior to the first dose of study drug).\n5. Concomitant use of medications that may prolong the QTc interval, potent immunosuppressive agents, or drugs that may cause interstitial lung disease (ILD) is prohibited during the treatment period. If co-administration is unavoidable, prior discussion with the coordinating center is required.\n6. Patients with active primary immunodeficiency (e.g., HIV infection), active hepatitis B, or active hepatitis C:\n\n   * HBsAg-positive patients may be eligible if HBV DNA is negative or appropriate antiviral therapy is being administered.\n   * HCV antibody-positive patients may be eligible if HCV RNA is negative or the patient has been cured after treatment.\n7. Patients with active interstitial lung disease (ILD) or a history of non-infectious pneumonitis requiring steroid therapy, including immune-therapy- or chemotherapy-related ILD or Grade ≥3 pulmonary complications. (Patients with previously resolved infectious pneumonia without current clinical significance may be eligible.)\n8. Pregnant or breastfeeding women.\n9. Patients with clinically significant cardiovascular disease within the past 12 months (e.g., congestive heart failure, symptomatic coronary artery disease, arrhythmias, myocardial infarction).\n10. Patients whose toxicities from prior anticancer therapy have not recovered to baseline or ≤ Grade 2.\n11. Patients who received any prior anticancer therapy within 14 days or localized radiotherapy within 7 days before the first dose of the study drug.\n12. Patients with a known hypersensitivity to the study drugs.\n13. Any condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the study.","ALL","20 Years",{"count":19,"type":20},69,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This clinical trial is designed to compare and evaluate the efficacy and safety of the combination therapy of Lurbinectedin plus Paclitaxel (Combination Arm) versus Paclitaxel monotherapy (Monotherapy Arm) in patients with extensive-stage small-cell lung cancer whose disease has progressed after first-line chemotherapy.",[26],"Carcinoma, Small Cell Lung","NOT_YET_RECRUITING","2026-06-05",{"date":30,"type":31},"2026-06-11","ACTUAL",{"date":33,"type":20},"2026-06",{"date":35,"type":20},"2029-02",{"name":37,"class":38},"Yonsei University","OTHER",1,{"id":41,"slug":4,"hasResults":10,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":10,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":50,"conditions":51,"keywords":57,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100629562","NCT07476287","Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer","A PHASE 2 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED TRANSFORMED SMALL CELL LUNG CANCER","Inclusion Criteria:\n\n* Male or female participants aged ≥18 years at the time of informed consent.\n* Histologically or cytologically confirmed T-SCLC. Participant must have had a prior diagnosis of NSCLC with EGFR mutation which transformed to SCLC following the treatment with TKI(s).\n* Participants have not received systemic therapy for T-SCLC.\n* Have at least one measurable lesion as the target lesion based on RECIST v1.1.\n* Have sufficient tumor tissue from the diagnosis of transformed SCLC available.\n* Eastern Cooperative Oncology Group performance status of 0 or 1.\n* Have a minimum life expectancy of \\>12 weeks.\n* Clinical laboratory values at screening within acceptable limits, as defined in the protocol, including: 1) Hematology, 2) Liver function and 3) Renal function.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n* Active or untreated CNS disease, including brain, brainstem, spinal cord, or meningeal metastases. Participants with definitively treated, clinically stable brain metastases may be eligible per protocol criteria. Participants with untreated asymptomatic brain metastases of longest diameter \\\u003C1 cm are permitted if all of the following criteria are met: absence of neurological symptoms, no need for corticosteroids, and brain metastasis has no evidence of edema or hemorrhagic features.\n* Leptomeningeal disease\n* Clinically significant risk of hemorrhage or fistula, including tumor necrosis\u002Fcavitation, invasion or compression of major blood vessels, airways, or critical organs, or risk of tracheoesophageal or pleuroesophageal fistula\n* History of another malignancy (other than NSCLC) within 3 years prior to first dose, except for malignancies with negligible risk of metastasis or death (eg, adequately treated carcinoma in situ, nonmelanoma skin cancer)\n* Unresolved toxicity from prior anti-tumor therapy that has not recovered to Grade ≤1 per NCI CTCAE v5.0 (except alopecia or irreversible toxicities deemed stable)\n* History of allogeneic organ or hematopoietic stem cell transplantation\n* Active autoimmune disease requiring systemic treatment within the past 2 years (Stable replacement therapy and selected low-risk autoimmune conditions are permitted per protocol)\n* Interstitial lung disease (ILD), pneumonitis, or significant pulmonary disease, including:\n\n  * Prior or current non-infectious pneumonitis requiring systemic therapy\n  * DLCO \\\u003C50% predicted\n  * Severe asthma, COPD, pulmonary embolism, or autoimmune lung involvement\n* Uncontrolled or clinically significant cardiovascular, cerebrovascular, metabolic, hepatic, or renal disease within 6 months prior to first dose\n* Baseline QTcF \\>480 msec\n* Major surgery or severe trauma within 4 weeks prior to first dose, or planned major surgery during the study\n* Clinically significant pleural effusion, pericardial effusion, or ascites requiring repeated drainage\n* History of significant bleeding disorders or recent major bleeding events\n* Clinically significant gastrointestinal conditions, including recent perforation, fistula, obstruction, or active bleeding\n* Active, uncontrolled, or symptomatic infection, including:\n\n  * Active TB\n  * Active hepatitis B or C\n  * Uncontrolled HIV infection\n* History of immunodeficiency\n* Severe hypersensitivity or allergic reactions to study intervention components or monoclonal antibodies\n* Psychiatric illness or medical condition, including recent suicidal ideation or behavior, that may increase risk or interfere with study participation\n* Prior anti-angiogenic therapy or other prohibited anti-tumor or immunomodulatory therapies per protocol-specified washout periods\n* Use of prohibited concomitant medications, including high-dose systemic corticosteroids, certain anticoagulants, or live vaccines within protocol-specified timeframes\n* Recent participation in another investigational study (within 30 days or 5 half-lives, whichever is longer)\n* Pregnant or breastfeeding participants, or unwillingness to comply with contraception requirements","18 Years",{"count":48,"type":20},40,[23],"This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy . Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. The study is for adults with Transformed Small Cell Lung Cancer (T-SCLC ). T SCLC is a rare lung cancer that happens when one type of lung cancer changes into a more aggressive type after treatment stops working.\n\nTo join the study, participants must meet the following conditions:\n\n* Are aged 18 years or older\n* Diagnosed with T-SCLC and have not received treatment for this type of lung cancer (a single cycle of chemotherapy may be permitted)\n* Prior diagnosis of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer treated with tyrosine kinase inhibitors (TKIs)\n* Have healthy organs based on medical tests and are in good physical condition\n\nAfter joining the study, adults will be given chemotherapy in addition to the study medicine. After this combination treatment is finished, the study medicine will be continued alone. Adults will receive the treatment through IV infusions (medicine given directly into a vein). All treatments will be done at clinical study sites, where a trained medical team will monitor adults during and after each visit.",[52,53,54,55,26,56],"Small Cell Lung Cancer","Small Cell Lung Cancer ( SCLC )","Transformed Small Cell Lung Cancer","Lung Neoplasms","Small Cell Cancer Of The Lung",[54,52],"RECRUITING","2026-06-03",{"date":61,"type":31},"2026-06-04",{"date":63,"type":20},"2026-05-15",{"date":65,"type":20},"2031-03-19",{"name":67,"class":68},"Pfizer","INDUSTRY",12,{"id":71,"slug":4,"hasResults":10,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":10,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":85,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100611589","NCT07242547","Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients","A Phase II Clinical Trial of Tarlatamab as Maintenance Treatment After Sequential Chemo-radiotherapy for Limited Stage SCLC Patients Not Eligible for Concurrent Chemo-radiotherapy","MERLIN","Inclusion Criteria:\n\n* Histologically or cytologically documented new diagnosis of LS-SCLC by histology or cytology from brushing, washing, or needle aspiration. Mixed tumors are not eligible.\n* Patients who:\n\n  1. were treated with sequential chemo-radiotherapy\n  2. were treated only with chemotherapy\n* Have at least one lesion that meets criteria for being measurable or non-measurable, as defined by RECIST 1.1.\n* Has completed chemo-radiation or chemotherapy alone without progression of disease per RECIST v1.1\n* Be male or female ≥18 years of age inclusive, on the day of signing informed consent.\n* Have a life expectancy of at least 3 months from the study start.\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days prior to the first dose of study intervention.\n* Toxicities attributed to chemo-radiotherapy treatment have to be resolved to grade ≤1, unless otherwise specified.\n* No clinically significant electrocardiogram (ECG) findings\n* Correct pulmonary function without oxygen supplementation\n* Have voluntarily agreed to participate by giving written consent for the study prior to any specific protocol procedures.\n* Have adequate organ function (hematological and biochemistry parameters).\n\nExclusion Criteria:\n\n* Patients expected to require any other form of radiation therapy for LS-SCLC as concurrent radiotherapy.\n* Extensive-stage SCLC (ES-SCLC) or any previous diagnosis of transformed non-small cell lung cancer. Mixed tumors (SCLC-NSCLC) are not eligible.\n* Has known history of, or active, neurologic paraneoplastic syndrome of autoimmune nature.\n* Has had major surgery within 4 weeks prior to first dose of study interventions.\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.\n* Has known history of a second malignancy other than SCLC, unless potentially curative treatment has been completed with no evidence of malignancy for at least 3 years since the initiation of that therapy.\n* Uncontrolled intercurrent active infection at the time of enrollment requiring systemic therapy.\n* Evidence of interstitial lung disease or active, non-infectious pneumonitis.\n* History of solid organ transplantation.\n* Myocardial infarction and\u002For symptomatic congestive heart failure (New York Heart Association \\>class II) within 6 months prior to first dose of study treatment.\n* Has a known history of Human Immunodeficiency Virus (HIV) infection.\n* Has a known history of Hepatitis B or known active Hepatitis C virus infection.\n* Has a known history of active tuberculosis.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Has serious nonhealing wound, ulcer, or bone fracture within 28 days before first dose of study intervention.\n* Female subjects of childbearing potential unwilling to use protocol specified method of contraception during treatment and for an additional 60 days after the last dose of study treatment.\n* Female subjects who are breastfeeding or who plan to breastfeed while on study through 60 days after the last dose of study treatment.\n* Female subjects planning to become pregnant or donate eggs while on study through 60 days after the last dose of study treatment.\n* Female subjects of childbearing potential with a positive pregnancy test assessed at screening by a highly sensitive serum pregnancy test.\n* Male subjects with a female partner of childbearing potential who are unwilling to practice sexual abstinence or use contraception during treatment and for an additional 60 days after the last dose of study treatment.\n* Male subjects with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 60 days after the last dose of study treatment.\n* Subject has known sensitivity to any of the products or components to be administered during dosing.",{"count":78,"type":20},37,[23],"This is an open-label, phase II, exploratory and multi-centre clinical trial. 37 Limited stage SCLC patients not eligible for concurrent chemo-radiotherapy will be enroll.\n\nPatients will be enrolled in the trial after receiving sequential chemo-radiotherapy, if there is no progression disease, patients will be treated with maintenance Tarlatamab.\n\nPatients will receive maintenance with Tarlatamab IV until disease progression unacceptable toxicity, patient or physician decision to discontinue or death.\n\nThe primary objective is to evaluate the Progression free survival (PFS).\n\nPatient accrual is expected to be completed within 2 years. Treatment and follow-up are expected to extend the study duration to a total of 5 years. Patients will be followed for 2 years after enrollment. The study will end once survival follow-up has concluded.",[82,26,83,84],"Limited-stage Small-cell Lung Cancer","Respiratory Tract Neoplasms","Thoracic Neoplasms",[86,87,88,89,90,91],"Non small cell lung cancer","Tarlatamab","Maintenance treatment","Antineoplastic Agents","Chemo-radiotherapy","Immunotherapy","2026-04-29",{"date":94,"type":31},"2026-05-05",{"date":96,"type":20},"2026-05-28",{"date":98,"type":20},"2030-06-01",{"name":100,"class":38},"Fundación GECP",20,{"id":103,"slug":4,"hasResults":10,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":10,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":111,"conditions":112,"keywords":116,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":39},"100482106","NCT05557708","A Safety Study of 212Pb-Pentixather Radioligand Therapy","Biodistribution of 68Ga Pentixafor in Patients With Small Cell Lung Carcinoma (SCLC)","Inclusion Criteria:\n\n* ability to provide independent consent\n* adequate bone marrow function (platelet count ≥ 100,000; hemoglobin of ≥ 10 g\u002FdL; neutrophil count ≥ 1,500 cells\u002Fmm3)\n* adequate kidney function (creatinine clearance of ≥ 50 mL\u002Fmin using the Cockcroft-Gault equation\n* adequate liver function (serum bilirubin ≤ 3x the upper limit of normal, AST ≤ 5x the upper limit of normal, and ALT ≤ 5x the upper limit of normal)\n* failed initial therapy or declined further therapy known to confer benefit\n* have at least one lesion ≥ 2 cm that is positive for CXCR4 as demonstrated by Lead-203 Pentixather SPECT\u002FCT\n\nExclusion Criteria:\n\n* major surgery within 4 weeks of consent\n* antoher investigational agent within 4 weeks of consent\n* uncontrolled illness including, but not limited to, ongoing or active infection that would necessitate a delay in therapy or cause a hospital admission, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, hepatic cirrhosis or severe impairment, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* prior solid organ transplant\n* cytotoxic or antineoplastic therapy within 21 days of consent (42 days for nitrosoureas)\n* antibody therapy within the 21 days of consent\n* allogenic bone marrow or stem cell transplant, or any stem cell infusion, within 84 days of consent\n* pregnancy\n* breastfeeding\n* refusal to comply with birth control requirements during study",{"count":101,"type":20},[110],"EARLY_PHASE1","This is a first-in-human clinical trial evaluating the safety of an alpha-radiation treatment (Lead-212 labelled Pentixather) in patients who have been diagnosed with, and previously treated, for atypical carcinoid lesions of the lung.",[113,114,115],"Carcinoid Tumor Lung","Neuroendocrine Tumor of the Lung","Carcinoma, Small-Cell Lung",[117,118,119,120,121,122],"radioligand therapy","pentixather","Lead 203","Lead 212","alpha therapy","dosimetry","2025-07-02",{"date":125,"type":31},"2025-07-08",{"date":127,"type":20},"2026-07-01",{"date":129,"type":20},"2030-06-30",{"name":131,"class":38},"Yusuf Menda",""]